問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

List

1336Cases

2007-12-25 - 2009-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2006-10-01 - 2009-04-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2007-09-01 - 2008-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Terminated14Sites

2007-05-01 - 2009-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Study ended11Sites

2005-12-01 - 2007-12-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Study ended10Sites

2017-10-01 - 2021-12-31

Phase II

Phase II, Randomized, Double-blind, Clinical Tial of the Safety and Immunogenicity of a Tetravalent Dengue Virus Vaccine Admixture TV005 in the Elderly Aged 50-70 Years in Taiwan

  • Condition/Disease

    Dengue

  • Test Drug

    tetravalent live attenuated dengue vaccine admixture TV005

Participate Sites
4Sites

Not yet recruiting2Sites

Terminated1Sites

陳彥旭
Kaohsiung Municipal Gangshan Hospital

未分科

2016-06-01 - 2025-05-31

IIT

Phase III

Neo-Adjuvant study with the PDL1-directed antibody in Triple Negative Locally Advanced Breast Cancer undergoing treatment with nabpaclitaxel and carboplatin

  • Condition/Disease

    Triple Negative Locally Advanced Breast Cancer

  • Test Drug

    atezolizumab (MPDL3280A)

Participate Sites
7Sites

Terminated5Sites

曾令民
Taipei Veterans General Hospital

Division of General Surgery

侯明鋒
Kaohsiung Municipal Gangshan Hospital

未分科

2018-07-31 - 2020-01-31

Phase III

A Double-blind, Randomized, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Imidafenacin in Patients with Overactive Bladder

  • Condition/Disease

    Overactive Bladder

  • Test Drug

    Uritos

Participate Sites
12Sites

Terminated11Sites

2014-10-01 - 2024-12-30

Phase II

A PHASE II, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MCS® IN PROSTATE CANCER PREVENTION

  • Condition/Disease

    PROSTATE CANCER

  • Test Drug

    MCS®

Participate Sites
21Sites

Recruiting6Sites

Study ended15Sites

2009-12-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

1 87 88 89 90 91 134
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB